Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

Recruiting

Phase 1

ThymalfasinThymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

Sponsor:

The Methodist Hospital Research Institute

Code:

NCT06821100

Conditions

Vaccine Response

COVID-19 Vaccine

Immune Response to Covid 19 Vaccination

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Accepted

Interventions

Thymalfasin (Thymosin alpha 1, Ta1)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by The Methodist Hospital Research Institute on 2025-02-11.